iRhythm/$IRTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iRhythm
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Ticker
$IRTC
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
2,000
ISIN
US4500561067
Website
iRhythm Metrics
BasicAdvanced
$4.8B
-
-$3.14
1.45
-
Price and volume
Market cap
$4.8B
Beta
1.45
52-week high
$154.51
52-week low
$55.92
Average daily volume
495K
Financial strength
Current ratio
5.712
Quick ratio
5.4
Long term debt to equity
830.049
Total debt to equity
848.672
Interest coverage (TTM)
-4.85%
Profitability
EBITDA (TTM)
-58.414
Gross margin (TTM)
69.39%
Net profit margin (TTM)
-15.89%
Operating margin (TTM)
-10.38%
Effective tax rate (TTM)
-1.23%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-4.37%
Return on equity (TTM)
-111.13%
Valuation
Price to revenue (TTM)
7.673
Price to book
55.78
Price to tangible book (TTM)
56.34
Price to free cash flow (TTM)
-4,490.528
Free cash flow yield (TTM)
-0.02%
Free cash flow per share (TTM)
-3.37%
Growth
Revenue change (TTM)
20.54%
Earnings per share change (TTM)
-25.85%
3-year revenue growth (CAGR)
21.97%
3-year earnings per share growth (CAGR)
-9.40%
What the Analysts think about iRhythm
Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
Bulls say / Bears say
iRhythm Technologies received Japanese regulatory approval for its Zio ECG monitoring system, marking a significant step in expanding its market presence in the world's second-largest medical device market. (globenewswire.com)
The company reported a 17% year-over-year increase in revenue for Q3 2024, indicating strong demand for its products and services. (tradingview.com)
iRhythm's next-generation Zio monitor demonstrated longer wear duration and analyzable time compared to the prior generation, potentially improving diagnostic yield and enhancing its competitive edge. (globenewswire.com)
The company reported a net loss of $46.2 million for Q3 2024, an increase from the $27.1 million loss in Q3 2023, raising concerns about its path to profitability. (tradingview.com)
iRhythm is facing a shareholder lawsuit alleging misrepresentation of its Zio AT monitor's capabilities, which could lead to financial liabilities and damage to its reputation. (tradingview.com)
The company anticipates incremental expenses related to FDA remediation efforts, estimating approximately $11 million to $13 million in 2024 and a $15 million run rate per year going forward, which may impact its financial performance. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
iRhythm Financial Performance
Revenues and expenses
iRhythm Earnings Performance
Company profitability
iRhythm News
AllArticlesVideos
New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease
GlobeNewsWire·4 days ago
Robbins LLP Informs iRhythm Technologies, Inc. (IRTC) Investors That the Class Action Beat the Motion to Dismiss
GlobeNewsWire·1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRhythm stock?
iRhythm (IRTC) has a market cap of $4.8B as of June 27, 2025.
What is the P/E ratio for iRhythm stock?
The price to earnings (P/E) ratio for iRhythm (IRTC) stock is 0 as of June 27, 2025.
Does iRhythm stock pay dividends?
No, iRhythm (IRTC) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next iRhythm dividend payment date?
iRhythm (IRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for iRhythm?
iRhythm (IRTC) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.